-
Traditional Chinese medicine still has opportunities for sector valuation improvement, optimistic about three major directions
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];In the future, with the overall support of national policies, there are still opportunities for the valuation of traditional Chinese medicine.
js?cdnversion='+~(-new Date()/36e5)];In the future, with the overall support of national policies, there are still opportunities for the valuation of traditional Chinese medicine.
-
The State Administration for Market Regulation launched a national special action to stabilize the price and quality of epidemic-related drugs and medical supplies
Time of Update: 2023-02-03
According to the news of the State Administration for Market Regulation on the 4th, a few days ago, the State Administration for Market Regulation issued the "Notice of the State Administration for M
-
The State Food and Drug Administration approved the marketing of 13 symptomatic treatment drugs for new coronavirus infection
Time of Update: 2023-02-03
Annex: List of varieties serial number Name of the drug specification dosage form Marketing Authorization Holder 1 Acetaminophen vitamin C effervescent tablets Each tablet contains 330 mg of paracetamol and 200 mg of vitamin C Tablets Hainan Taosheng Pharmaceutical Science and Technology Research Institute Co.
-
More than 100 million yuan of hypoglycemic drug market, ushered in another evaluated pharmaceutical company!
Time of Update: 2023-02-03
On January 5, Hanyu Pharmaceutical issued an announcement that the company received the "Drug Registration Certificate" issued by the State Medical Products Administration, and the company's hypoglycemic drug "vildagliptin tablets" was approved for marketing and deemed to have passed the consistency evaluation.
-
The ophthalmic treatment market has reached 210 billion yuan, and the track has ushered in nugget fever
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];The eye is a very important organ for humans, and as eye health becomes more and more important, the size of the ophthalmic medical market has begun to show a steady growth trend.
-
Shaanxi issued a rehabilitation guide manual for people infected with the new coronavirus
Time of Update: 2023-02-03
2. Major health problems and rehabilitation suggestions during the recovery period According to the World Health Organization's "Guidelines for Personal Recovery of New Coronary Pneumonia", combined with clinical observation and population surveys, people recovering from new coronavirus infection currently have the following health problems: shortness of breath, limited physical activity and exercise, decreased physical strength and fatigue, hoarseness and cough, swallowing problems, smell and taste problems, anxiety, depression and sleep problems, body pain, etc.
-
In 2023, the pharmaceutical industry after the change of senior management is worth waiting for!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Shortly after the beginning of 2023, the market reported that Hengrui Pharmaceutical, the "first brother of medicine", announced internally that Jiang Ningjun, who had been one of the founders of CStone Pharmaceutical, was appointed as the deputy general manager and chief strategy officer of Hengrui Pharmaceutical, and he was responsible for the company's clinical research and business development.
-
A batch of new regulations came into effect on January 1, involving issues related to the people's vital aspects such as old-age care and medical insurance
Time of Update: 2023-02-03
In addition to basic function software, mobile phone pre-installed apps can be uninstalled The Ministry of Industry and Information Technology and the Cyberspace Administration of China further standardize the presetting behavior of mobile intelligent terminal application software.
-
Circular of the State Food and Drug Administration on the Results of National Medical Device Supervision and Sampling (No. 4) (No. 63 of 2022)
Time of Update: 2023-02-03
0ml/pc/box DANAE Line Z1 2021-03-26 C1053J1 Beijing Municipal Drug Administration China Academy of Food and Drug Control Free sodium hyaluronate content serial number Label the product name Spot checked Indicate the medical device registrant and recordation holder Specifications and models Date of manufacture/batch number/factory number sampling Inspection Non-compliance with standard provisions 1 Electric wheelchair car Shanxi Kangwanjia Medical Equipment Chain Co.
-
28 proprietary Chinese medicines lit up! 6 varieties of more than 1 billion lead the way, and 17 exclusive varieties dominate the screen
Time of Update: 2023-02-03
The 17 proprietary Chinese medicines are exclusive varieties, including Yangzijiang Pharmaceutical's Lanqin Oral Liquid, Jichuan Pharmaceutical's Pudi Blue Anti-inflammatory Oral Liquid, Sanli Pharmaceutical's Open Throat Sword Spray, Sunflower Pharmaceutical's Pediatric Lung Fever, Cough and Asthma Oral Liquid, and Darentang's Clear Throat Drop Pill.
-
Several measures to further strengthen the scientific supervision of Chinese medicines and promote the inheritance, innovation and development of Chinese medicines
Time of Update: 2023-02-03
Give full play to the important role of GAP in the quality supervision of the production of Chinese medicinal materials, set up a national GAP expert working group, study and improve the implementation work promotion plan and supporting technical requirements, and promote the standardization, industrialization and large-scale planting and breeding of Chinese medicinal materials.
-
In 2023, favorable policies will continue to increase the weight of traditional Chinese medicine, and the long-term opportunities of the sector will be optimistic by institutions
Time of Update: 2023-02-03
On the trading day of the New Year in 2023, the traditional Chinese medicine sector changed in early trading, and in the morning of January 3, Fangsheng Pharmaceutical and Zhongsheng Pharmaceutical touched the limit of increase, and individual stocks such as Kangbei, Hongri Pharmaceutical, and Kunming Pharmaceutical followed suit.
-
Recently, medical companies have been taking frequent actions! Busy with acquisition, construction of R&D bases...
Time of Update: 2023-02-03
On January 4, 2023, it was learned that Canon Medical plans to spend US$300 million to open a new subsidiary, Canon Healthcare USA, in the United States, aiming to strengthen its imaging business and focus sales and investments on the US market.
-
The development focus of traditional Chinese medicine innovative pharmaceutical enterprises, long-term opportunities are emerging
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];Traditional Chinese medicine is one of the characteristics of Chinese medicine, in recent years, the approval speed of domestic innovative Chinese medicine drugs has increased significantly, and Chinese medicine innovative drugs and exclusive varieties have a greater competitive advantage in medical insurance procurement, in this context, some pharmaceutical companies have begun to take traditional Chinese medicine innovative drugs as the focus of the company's development.
-
China's domestic extracorporeal membrane oxygenation therapy (ECMO) products have been approved for marketing
Time of Update: 2023-02-03
According to the needs of epidemic prevention and control, in order to ensure the treatment needs of severe patients with novel coronavirus pneumonia, on January 4, 2023, the State Food and Drug Admi
-
Future strategic planning of pharmaceutical companies, new drug research and development into the focus of development!
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On January 4, Genting Xinyao released its strategic plan for the next two years and beyond, the company will further transform into a comprehensive biopharmaceutical company, realize the whole industry chain layout, including strong independent R&D and licensing capabilities, clinical development capabilities, and large-scale production and commercialization capabilities.
-
Domestic pharmaceutical companies are active in cross-border license-in, and these fields have become hot
Time of Update: 2023-02-03
In addition, it is worth mentioning that on November 15, 2022, Huadong Medicine also announced that its US partner ImmunoGen, Inc. has announced that its world's first (first-in-class) ADC drug ELAHERE (mirvetuximab soravtansine-gynx, R&D code: IMGN853, HDM2002) for the treatment of platinum-resistant ovarian cancer Obtained accelerated marketing approval from the US Food and Drug Administration (FDA).
-
In 2023, pharmaceutical companies will start "buying, buying, buying" again!
Time of Update: 2023-02-03
On the same day, Fengyuan Pharmaceutical disclosed its plan to acquire assets, and the company purchased 100% of the equity of Tigermed Technology held by Tigermed Biologics by issuing shares and raised supporting funds.
-
The pharmaceutical and biological industries have frequently reduced their holdings, and at the beginning of the new year, many pharmaceutical companies have issued announcements to reduce their holdings
Time of Update: 2023-02-03
On January 4, Jichuan Pharmaceutical was reduced by 931,500 shares by Shanghai Stock Connect, and the new holdings were 39,609,300 shares, accounting for 4.
On January 4, Jichuan Pharmaceutical was reduced by 931,500 shares by Shanghai Stock Connect, and the new holdings were 39,609,300 shares, accounting for 4.
-
The internationalization of domestic innovative drugs has accelerated, and a number of new drugs have been approved by the FDA for clinical trials
Time of Update: 2023-02-03
, Ltd. announced that the company's self-developed innovative antibody conjugate drug (ADC) RC108 for injection has obtained the clinical trial approval of the US Food and Drug Administration (FDA) to carry out clinical research in patients with solid tumors with positive c-Met expression.
